Kasia Siwek, Sanofi's country medical head for Australia and NZ, said, “At Sanofi, we are proud of our ongoing work with both the Australian clinical community and the government to broaden access to LIBTAYO as a first-line treatment for eligible Australians diagnosed with metastatic NSCLC. …
Sanofi welcomes new lung cancer listing for immune checkpoint inhibitor
April 4, 2024 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Week in Review' Podcast - 27 February
February 27, 2026 - - Podcast -
EU backs Australian-led consortium with up to $250m to advance next-generation influenza vaccines
February 26, 2026 - - Latest News -
United front forms across Asia Pacific to change the future of Pulmonary Arterial Hypertension
February 26, 2026 - - Latest News -
There are, in effect, two Pharmaceutical Benefits Schemes operating in Australia today
February 26, 2026 - - Latest News -
Reading the room on reform might mean following the Budget message
February 25, 2026 - - Latest News -
Weight-loss medicines approved in New Zealand, and recommended for funding, but pathway remains unclear
February 25, 2026 - -
Neurizon advances ALS drug program as funding, trials and global partnerships gain momentum
February 25, 2026 - - Australian Biotech